Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Historical Cohort Study to Investigation of Statins Safety in Covid-19 Hospitalized Patients Publisher



Nateghi S1 ; Gomari MM2 ; Hosamirudsari H3 ; Behnoush B4 ; Razmjoofard A5 ; Azimi G1 ; Ordookhani S1 ; Jafarpour A6, 7 ; Faraji N1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Infectious Diseases, Baharloo Hospital, Railway Square, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Forensic Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Gerash Amir-al-Momenin Medical and Educational center, Gerash University of Medical Science, Gerash, Iran
  7. 7. Research center for clinical virology, Tehran university of medical science, Tehran, Iran

Source: Therapies Published:2022


Abstract

Background and objectives: A notable proportion of COVID-19 patients need statins for their co-existing conditions. Statins possess several anti-inflammatory properties. We have attempted to describe potential association of exposure to statins and severity of COVID symtpoms in a historical study in hospitalized COVID-19 patients. Methods: This single-center, historical cohort study was performed in Baharloo hospital as a referral hospital for COVID-19 patients in Tehran. Patients were divided into two groups; 163 statins users and 547 non-users. Mortality rate, intensive care unit (ICU) admission and length of hospitalization were compared between studied groups. In addition, during the investigation, pre-existing conditions were evaluated for groups. If a significant difference was observed between groups, the feature was considered in the adjustment of the odds ratio. Results: At the beginning, statistical analysis study showed that statins users had significantly (p < 0.0001) higher mortality rate, ICU admission and length of hospitalization. But after implementation of variables such as age, sex, diabetes, hypertension status, stroke, dyslipidemia, cardiovascular diseases, chronic kidney disease (CKD), corticosteroids, renin-angiotensin-aldosterone axis inhibitors and proton pump inhibitors (PPIs) for adjustment of the odds ratio, a considerable alteration appeared in the studied values. Following adjustment of odds ratio it was shown that statins did not change mortality (95% CI, OR 0.71 (0.41–1.22), p = 0.22), ICU admission (95% CI, OR 1.05 (0.66–1.66), p = 0.835) and length of hospitalization (95% CI, OR 1.30 (0.78–2.17), p = 0.311). In addition, we found that statins could not decrease inflammatory markers in COVID-19 infected patients. Conclusion: The use of statins did not seem to change outcomes in COVID19. © 2021 Societe francaise de pharmacologie et de therapeutique
Related Docs
View other Related Docs
1. Short-Term Efficacy of Moderate-Intensity Rosuvastatin in Coronavirus Disease 2019 Patients: A Randomized Clinical Trial, Journal of Investigative Medicine (2025)
2. Effects of Statins on Renin–Angiotensin System, Journal of Cardiovascular Development and Disease (2021)
3. The Role of Lovastatin in the Attenuation of Covid-19, International Immunopharmacology (2021)
4. Covid-19’S Immuno-Pathology and Cardiovascular Diseases, Journal of Investigative Medicine (2023)
5. Atorvastatin Versus Placebo in Icu Patients With Covid-19: Ninety-Day Results of the Inspiration-S Trial, Thrombosis and Haemostasis (2023)
6. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)
7. Commentary: A Human Pluripotent Stem Cell-Based Platform to Study Sars-Cov-2 Tropism and Model Virus Infection in Human Cells and Organoids, Frontiers in Endocrinology (2020)
8. State-Of-The-Art of Nanodiagnostics and Nanotherapeutics Against Sars-Cov-2, ACS Applied Materials and Interfaces (2021)
Experts (# of related papers)
View all Related Experts
Hossein Khalili (3)
Mohammad Taghi Beigmohammadi (2)
Other Related Docs
9. Pharmacotherapy Considerations in Ckd Patients With Covid-19, a Narrative Review, Iranian Journal of Kidney Diseases (2020)
10. The Role of Inflammation in the Development of Complications Caused by Covid-19: A Review Study, Journal of Payavard Salamat (2022)
11. Recent Advances in Passive Immunotherapies for Covid-19: The Evidence-Based Approaches and Clinical Trials, International Immunopharmacology (2022)
12. Intermediate Versus Standard-Dose Prophylactic Anticoagulation and Statin Therapy Versus Placebo in Critically-Ill Patients With Covid-19: Rationale and Design of the Inspiration/Inspiration-S Studies, Thrombosis Research (2020)
13. Diabetes As One of the Long-Term Covid-19 Complications: From the Potential Reason of More Diabetic Patients’ Susceptibility to Covid-19 to the Possible Caution of Future Global Diabetes Tsunami, Inflammopharmacology (2023)
14. Renin-Angiotensin-Aldosterone Axis Inhibition Improves Outcome of Diabetic Patients With Chronic Hypertension and Covid-19: An Iranian Perspective, Advanced Biomedical Research (2022)
15. Complement System As the Potential Therapeutic Target in the Management of Covid-19 Patients, Trends in Immunotherapy (2022)
16. Association of Clinical Characteristics, Antidiabetic and Cardiovascular Agents With Diabetes Mellitus and Covid-19: A 7-Month Follow-Up Cohort Study, Journal of Diabetes and Metabolic Disorders (2021)
17. The Evaluation of Hematological Parameters and Their Correlation With Disease Prognosis in Covid-19 Disease in Iran, International Journal of Hematology-Oncology and Stem Cell Research (2023)